Volume 100, Issue 1 pp. 184-186

Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma

Claude Preudhomme

Claude Preudhomme

U124 INSERM, Lille,

Laboratoire d'Hématologie, Hôpital Calmette, Lille,

Search for more papers by this author
Mickaël Vanrumbeke

Mickaël Vanrumbeke

U124 INSERM, Lille,

Search for more papers by this author
Laurence Detourmignies

Laurence Detourmignies

Service des Maladies du Sang, Hôpital Huriez, Lille,

Search for more papers by this author
Thierry Facon

Thierry Facon

Service des Maladies du Sang, Hôpital Huriez, Lille,

Search for more papers by this author
Pascale Lepelley

Pascale Lepelley

Laboratoire d'Hématologie, Hôpital Calmette, Lille,

Search for more papers by this author
Thierry Soussi

Thierry Soussi

U301 INSERM, Université P. et M. Curie, Paris, France

Search for more papers by this author
Pierre Fenaux

Pierre Fenaux

U124 INSERM, Lille,

Service des Maladies du Sang, Hôpital Huriez, Lille,

Search for more papers by this author
First published: 25 December 2001
Citations: 3
Dr Preudhomme Laboratoire d'Hématologie A, Hôpital A. Calmette, Boulevard du Pr. Leclerc, 59037 Lille, France.

Abstract

In several types of solid tumours, circulating antibodies to p53 are seen in about a third of cases with a p53 mutation, but are absent in cases without p53 mutation. Therefore detection of those antibodies has relatively low sensitivity but high specificity in the detection of p53 mutations.

We looked for circulating p53 antibodies by ELISA in 56 adult non-Hodgkin's lymphoma (NHL) and 80 multiple myeloma cases. A certain or highly probable p53 mutation was found by SSCP analysis, immunocyto- or immunohisto-chemistry in 8/35 (23%) NHL cases and 2/19 (10%) MM cases analysed by these techniques. None of the 80 MM cases and only one of the 56 cases of NHL had circulating p53 antibodies. The positive case had Burkitt's lymphoma and a p53 missense mutation at codon 273. Thus, very few MM and NHL patients with a p53 mutation develop p53 antibodies and this test does not appear to be useful in haematological malignancies.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.